Abstract: The present invention discloses a polymeric lanthanum nanocomposite, and a preparation method and application thereof and relates to the field of environmental functional materials. The preparation method includes the following steps: (1) mixing lanthanum chloride heptahydrate with concentrated hydrochloric acid and dissolving the mixture in alcohol, adding a resin polymer, and stirring at room temperature; (2) draining the resin after the stirring for use; (3) adding the resin to a precipitant solution, and stirring at room temperature and then filtering out the resin; and (4) washing the resin with water until the resin is neutral, adding a NaCl solution, stirring and then filtering out the resin, and drying to obtain the polymeric lanthanum nanocomposite. The prepared polymeric lanthanum nanocomposites have a relatively more uniform distribution, and show a higher phosphorus adsorption rate.

Abstract: The present application belongs to the field of medicinal chemistry, and relates to crystals of an aniline pyrimidine compound serving as an EGFR inhibitor. Specifically, the present application relates to crystal A, crystal B and crystal C of N-(2-((2-(dimethyl amino)ethyl)(methyl)amino)-4-methoxy-5-(4-(3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-1-base)pyrimidine-2-base amino)phenyl)acrylamide (formula I) hydrochloride, and also relates to the method for preparing the crystal A, the crystal B and the crystal C, a crystal composition comprising the crystal A, the crystal B, and the crystal C, a pharmaceutical composition comprising the crystal A, the crystal B and the crystal C or the crystal composition thereof, and medical uses thereof. The crystal A, the crystal B and the crystal C in the present application has the advantages of high purity, high crystallization degree, good stability and the like.

Abstract: The present application belongs to the field of medicinal chemistry, and relates to crystals of an aniline pyrimidine compound serving as an EGFR inhibitor. Specifically, the present application relates to crystal A, crystal B and crystal C of N-(2-((2-(dimethyl amino)ethyl)(methyl)amino)-4-methoxy-5-(4-(3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-1-base)pyrimidine-2-base amino)phenyl)acrylamide (formula I) hydrochloride, and also relates to the method for preparing the crystal A, the crystal B and the crystal C, a crystal composition comprising the crystal A, the crystal B, and the crystal C, a pharmaceutical composition comprising the crystal A, the crystal B and the crystal C or the crystal composition thereof, and medical uses thereof. The crystal A, the crystal B and the crystal C in the present application has the advantages of high purity, high crystallization degree, good stability and the like.

Abstract: A vehicle seat is equipped with a seat tilt mechanism capable of adjusting the amount one seat component is tilted relative to another. The tilt mechanism can couple a seat frame with a seat pan to adjust the relative amount of tilt therebetween. The tilt mechanism includes a housing and a bracket in sliding engagement with a surface of the housing that faces away from the seat pan during use. The bracket may include a bearing surface in sliding engagement with the housing. The bracket can be monolithic with generally U-shaped side walls extending away from the seat pan on opposite sides of the housing. Each side wall may extend partially around the housing with the seat pan providing structure that closes off the open end of the U-shape. The mechanism includes an optional cap on the seat pan side of the housing that may provide a low-friction bearing surface.